OPKO Health/$OPK
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About OPKO Health
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.
- Ticker
- $OPK
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 2,275
- Headquarters
- Miami, United States
- Website
- www.opko.com
OPKO Health Metrics
BasicAdvanced
$1.2B
-
-$0.09
1.50
-
Price and volume
Market cap
$1.2B
Beta
1.5
52-week high
$1.77
52-week low
$0.98
Average daily volume
4.3M
Financial strength
Current ratio
3.349
Quick ratio
2.651
Long term debt to equity
0.317
Total debt to equity
0.336
Interest coverage (TTM)
-3.73%
Profitability
EBITDA (TTM)
-78.172
Gross margin (TTM)
19.47%
Net profit margin (TTM)
-12.40%
Operating margin (TTM)
-28.56%
Effective tax rate (TTM)
8.71%
Revenue per employee (TTM)
$260,000
Management effectiveness
Return on assets (TTM)
-5.52%
Return on equity (TTM)
-5.88%
Valuation
Price to revenue (TTM)
2.201
Price to book
1.05
Price to tangible book (TTM)
41.41
Price to free cash flow (TTM)
-9.653
Free cash flow yield (TTM)
-10.36%
Free cash flow per share (TTM)
-0.172
Growth
Revenue change (TTM)
-11.47%
Earnings per share change (TTM)
-63.39%
3-year revenue growth (CAGR)
-12.18%
10-year revenue growth (CAGR)
-5.79%
3-year earnings per share growth (CAGR)
-30.48%
10-year earnings per share growth (CAGR)
-8.96%
What the Analysts think about OPKO Health
Analyst ratings (Buy, Hold, Sell) for OPKO Health stock.
Analyst projections of the future price of OPKO Health stock.
Bulls say / Bears say
Labcorp has agreed to buy selected BioReference assets for $722 million in cash at closing, with up to $150 million more tied to 4Kscore sales. If completed, the sale could materially strengthen OPKO’s resources and let it concentrate on pharmaceuticals. (OPKO Health)
OPKO’s second-quarter revenue rose to $163.5 million and its operating loss narrowed to $7 million from $60 million a year earlier. Its pharmaceutical segment also returned to operating income, offering signs of improvement beyond the planned lab sale. (OPKO Health)
OPKO has five ModeX programmes in clinical trials and has begun a Phase I/IIa study of its GLP-1/glucagon candidate. Further clinical progress could give the company growth drivers beyond its established products, though these programmes remain early-stage. (OPKO Health)
The Labcorp deal would remove BioReference’s clinical and women’s health testing, urology and 4Kscore operations, leaving OPKO with a smaller recurring diagnostics business. The $150 million earnout is conditional on 4Kscore sales, so the full announced value is not assured. (OPKO Health)
Despite the narrower quarterly loss, OPKO used $62.8 million of cash in operations during the first half of 2026. Management’s third-quarter outlook also put costs and expenses above expected revenue, leaving the company reliant on asset sales and financing while it funds its business and research. (OPKO Health, OPKO Health)
OPKO disclosed an appealed foreign tax assessment of about $246 million. An adverse decision could create a substantial liability and put pressure on its cash resources. (OPKO Health)
Data summarised monthly by Lightyear AI. Last updated on 15 Oct 2026.
OPKO Health Financial Performance
Revenues and expenses
OPKO Health Earnings Performance
Company profitability
Upcoming events
No upcoming events
OPKO Health News
AllArticlesVideos
Funds containing OPKO Health
Fund name | Fund size | $OPK weighting |
|---|---|---|
iShares Ageing Population$AGED | $953M | 0.08% |
iShares Ageing Population€AGED | $903M | 0.08% |
iShares Ageing Population£AGES | $953M | 0.08% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.03% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.03% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.